Peptide Therapy in Ann Arbor: The Complete Clinical Guide to Peptide Care Near You

A patient sits down with normal thyroid labs, a normal metabolic panel, and a referral note that reads: "Reports fatigue and slow recovery. Labs unremarkable." They used to train hard and recover overnight. Now one hard session costs them two days. Nothing on paper is wrong, and yet something clearly is.

This is the gap where peptide therapy operates.

Start Here: The Arbour Peptide Therapy Library

This is the main guide to peptide therapy in Ann Arbor and the surrounding area. If you arrived with a more specific question, these companion articles each go deep on one thing:

• What peptides are and how peptide signaling works - the plain-language explainer, no clinical background needed.
• Peptides for injury recovery and tissue repair - BPC-157, TB-500 and GHK-Cu, and what the research does and does not establish.
• Labs and monitoring on a peptide protocol - which panels are drawn, what they track, and when dosing gets adjusted.
• Peptide therapy across Michigan - statewide access, telehealth, typical market pricing and how to vet a clinic.
• Comparing compounds: tesamorelin vs sermorelin vs ipamorelin and CJC-1295 vs sermorelin.
• Service pages: peptide therapy in Ann Arbor, sermorelin, BPC-157, and the full peptide program.

What Conventional Medicine Misses About Recovery and Repair

Most clinical training is oriented toward recognizing disease states, not declining cellular efficiency. Your labs can sit squarely within reference ranges while your mitochondria struggle, your tissue repair slows, and your metabolic signaling deteriorates. The standard approach offers NSAIDs for inflammation, stimulants for energy, and reassurance that nothing is technically wrong.

But something is wrong. Your body is receiving inadequate signals at the cellular level. Peptides are the language cells use to communicate - short chains of amino acids that bind to specific receptors and trigger precise biological responses. When those signals weaken with age, stress, or metabolic dysfunction, the downstream effects touch everything from wound healing to cognitive processing to body composition.

Conventional practice has no framework for optimizing what still functions. It waits for frank pathology. Peptide therapy intervenes earlier, at the level of cellular communication itself.

How Peptide Therapy Differs From Hormone Therapy

This distinction matters and is frequently blurred. Hormone therapy supplies the hormone itself - testosterone, estradiol, progesterone. Peptide therapy generally works upstream, signaling your body to produce or regulate its own output.

Growth hormone secretagogues, for example, stimulate your pituitary to release your own growth hormone in a pulsatile pattern closer to natural physiology, rather than introducing exogenous hormone. That is a mechanistically different proposition with a different side effect profile and a different regulatory category.

Many patients benefit from both. Hormone optimization restores deficient levels while peptides can improve the signaling environment those hormones operate in. If you want the fundamentals first, our plain-language guide to what peptides are and how they signal covers the basics before you get to protocols.

What the Evidence Actually Supports

Benefits vary substantially by compound, which is why blanket claims about "peptide therapy" as a single treatment should be treated with suspicion. Below are the categories where clinical interest is concentrated, with an honest note on the strength of evidence behind each.

Sleep Quality and Recovery

This is where patients most consistently report noticeable change, and it has a plausible mechanism. Growth hormone is preferentially secreted during deep, slow-wave sleep, and the two systems are reciprocally linked (Van Cauter et al., 2004; PMID 15135771). Growth hormone secretagogues are typically dosed at night specifically to work with that rhythm rather than against it.

Being precise matters here, because the mechanism and the outcome are not the same thing. In a small controlled crossover study, late-night injection of a ghrelin-receptor secretagogue raised growth hormone but did not increase slow-wave sleep (Moreno-Reyes et al., 1998; PMID 9612233). Deeper sleep and better next-day recovery are commonly reported by patients on these protocols, and that reporting is worth taking seriously, but it is clinical observation rather than large randomized trial data in healthy adults. The magnitude of benefit varies considerably between individuals.

Body Composition and Metabolism

This category contains both the strongest and the weakest evidence in all of peptide medicine, which is exactly why it needs separating.

On the strong end are the GLP-1 and dual-agonist medications. Tirzepatide is FDA-approved for type 2 diabetes and for chronic weight management, supported by large phase 3 trials: in SURMOUNT-1, mean weight reduction at 72 weeks was 15.0 to 20.9 percent depending on dose, versus 3.1 percent on placebo (Jastreboff et al., 2022; PMID 35658024). This is mainstream, evidence-backed pharmacology, and it forms part of our medical weight loss program.

Growth hormone secretagogues sit further down the evidence ladder for body composition. Growth hormone influences lean mass and fat metabolism, and tesamorelin specifically has phase 3 data showing a 15.4 percent treatment effect on visceral adipose tissue in a defined patient population (Falutz et al., 2010; PMID 20554713). Extrapolating that to general body recomposition in healthy adults goes beyond what the data currently establishes. A responsible protocol treats these as supportive of training and nutrition, not a substitute for either. If you are weighing one secretagogue against another, our tesamorelin, sermorelin and ipamorelin comparison lays out the differences side by side.

Injury Repair and Tissue Healing

Compounds such as BPC-157 and TB-500 attract enormous interest for tendon, ligament and gut healing, and this is the area where the gap between online claims and clinical evidence is widest.

The preclinical work is real and genuinely interesting. Animal studies have shown accelerated tendon, ligament, muscle and bone healing and improved gut mucosal integrity (Seiwerth et al., 2018; PMID 29998800). What does not yet exist is a body of large, well-controlled human trials. Anyone telling you these compounds are proven in humans is going beyond the published evidence.

That makes them investigational, and it is why they belong under clinical supervision, where a clinician can weigh the evidence honestly against your situation, rather than ordered from an unregulated website. For structural injuries with established treatment pathways, our regenerative medicine options including platelet-rich plasma rest on a considerably deeper human evidence base. Our full write-up on peptides for injury recovery and tissue repair covers the mechanisms and the evidence gaps in detail, and the BPC-157 service page explains how it is prescribed here.

Energy, Cognitive Function and Cellular Aging

Compounds in this group, including MOTS-c, epithalon, NAD+, semax and selank, target mitochondrial function, telomere biology, and neurological signaling. Mechanistically they are among the most scientifically interesting molecules in the category.

They are also the furthest from clinical proof. Human data is limited, and longevity outcomes in particular are extraordinarily difficult to demonstrate because they require decades of follow-up that has not happened yet. These are appropriately described as investigational, and any clinic presenting them as established anti-aging treatments is overstating the case. For the broader framework we use to separate proven interventions from investigational ones, see our longevity medicine program.

Libido and Sexual Wellness

PT-141, known generically as bremelanotide, breaks the pattern. Unlike most compounds in this space it went through the full FDA approval process for hypoactive sexual desire disorder in premenopausal women, on the strength of two randomized phase 3 trials in 1,267 women (Kingsberg et al., 2019; PMID 31599840). It acts through melanocortin receptors in the central nervous system rather than on blood flow, which makes it mechanistically distinct from the more familiar erectile dysfunction medications. Prescribing it outside that specific indication is a clinical judgment call made with your clinician, and is usually considered alongside a full sexual wellness evaluation rather than in isolation.

How Peptides Are Regulated, and Why the Prescriber Matters

Patients deserve a direct answer here, because a lot of clinics avoid the question entirely.

Peptides fall into three distinct regulatory categories. Some are fully FDA-approved medications with the trial data to match, including tirzepatide and bremelanotide. Some are compounded by licensed pharmacies and prescribed by clinicians using professional judgment. And some are genuinely investigational, with promising mechanisms and limited human data.

The regulatory landscape for compounded peptides has been actively changing, and 2026 has brought continued federal review of which compounds may be compounded and under what conditions. Any clinic that gives you a confident, permanent-sounding answer about availability is not being straight with you. At Arbour Longevity, which specific compounds are available is confirmed at the time of prescribing, subject to current FDA regulations, and discussed openly during your consultation.

The practical takeaway: this is a category where the prescriber matters enormously. Peptides are prescription medications. A licensed clinician evaluating your labs and history, prescribing and supervising your protocol, and sourcing from a licensed compounding pharmacy is a fundamentally different proposition from an unregulated website shipping vials labelled "for research use only."

What Most Patients Experience

The presentation we see benefit most often is a stalled repair process in someone whose conventional workup came back unremarkable: a tendon problem that has outlasted physical therapy and activity modification, recovery that no longer keeps pace with training, sleep that has stopped restoring.

On a supervised protocol, patients in that situation commonly report reduced morning stiffness and easier day-to-day recovery over the first several weeks, with function improving over a longer window. Individual results vary, no outcome is guaranteed, and part of the value of a monitored protocol is finding out early when something is not working so it can be changed or stopped.

Who Is a Good Candidate for Peptide Therapy

Peptide therapy at Arbour Longevity is not for everyone, and being clear about that upfront builds the trust good medicine requires.

Good candidates typically include adults over 30 experiencing age-related changes in recovery, energy, sleep, body composition or sexual function that have not responded adequately to lifestyle optimization alone. Athletes and active adults dealing with joint, tendon or soft tissue injuries that are healing slowly. Patients already on hormone optimization who want to complement their protocol with targeted regenerative support. And individuals pursuing a proactive longevity strategy focused on cellular and mitochondrial health.

Careful evaluation is needed for patients with a history of hormone-sensitive cancers, active inflammatory bowel disease, pregnancy or breastfeeding, or uncontrolled metabolic conditions. Any patient unwilling to complete baseline labs and ongoing monitoring is not a candidate at our clinic - the safety infrastructure is not optional.

The Arbour Longevity Approach to Peptide Protocols

Every protocol begins with comprehensive laboratory testing and a full clinical intake with Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC, a triple board certified nurse practitioner. Compounds are selected only where the labs and the clinical picture support them, sourced through licensed compounding pharmacies rather than research suppliers, and reviewed at defined intervals so dosing tracks your actual response rather than an average.

Written informed consent covering the regulatory status and known risk profile of each compound is completed before any protocol begins. Full outcomes are assessed at a three-month clinical review with follow-up labs. If you want the detail on which panels are drawn and what they are watching for, see our guide to peptide therapy labs and monitoring.

Protocols fall into six clinical categories: growth hormone support, metabolic and weight loss, regenerative and healing, sexual health, longevity, and cognitive performance. You can see the full service detail on our peptide therapy in Ann Arbor page and the wider peptide program, and if you want to know exactly how a first appointment runs, we have written up what to expect during your first session.

What Peptide Therapy Costs in Ann Arbor

Your first visit is $35, applied toward your treatment plan, and includes a full review of your labs, symptoms and goals. Peptide therapy programs start at $399 per month.

Specific protocol pricing depends on which compounds are clinically appropriate for your situation, which is why it is discussed at consultation rather than advertised as a flat rate. HSA and FSA cards are accepted. For a broader view of the market across the state, see our guide to peptide therapy across Michigan.

Frequently Asked Questions About Peptide Therapy in Ann Arbor

Where can I find peptide therapy near me in Ann Arbor?

Arbour Longevity is at 2217 Packard St #15, Ann Arbor, MI 48104, and sees patients Thursday through Monday, 10:00 to 19:00, closed Tuesday and Wednesday. Parking is free and directly outside, with no meters and no structure. Suite 15 is down a flight of stairs, so please call ahead on (734) 436-3357 if stairs are difficult for you and we will make arrangements.

Is peptide therapy legal in Michigan?

Yes. Peptide therapy prescribed by a licensed clinician and sourced from a regulated compounding pharmacy is legal in Michigan. Individual compounds sit in different regulatory categories - PT-141 is fully FDA-approved, while others are prescribed under clinical judgment within the compounding framework. Regulatory status can change, and we monitor it continuously.

Are peptides the same as steroids or testosterone?

No. Peptides are signaling molecules that stimulate your body's own processes. Testosterone is a hormone, and anabolic steroids are synthetic hormone derivatives. Growth hormone secretagogues stimulate your pituitary to release your own growth hormone rather than introducing exogenous hormone. The mechanisms, side effect profiles and regulatory categories are entirely different.

How long does peptide therapy take to work?

This varies by compound and individual response. Sleep and recovery changes on growth hormone secretagogues are often reported within two to four weeks. Regenerative compounds typically show progress within two to six weeks. Tirzepatide generally produces measurable metabolic change within four weeks. Full protocol outcomes are assessed at the three-month review.

Can I combine peptide therapy with hormone optimization?

Yes, and many patients do. The two address different but complementary pathways - hormone therapy restores a deficient level while peptides work on the signaling environment. Because both are managed by the same clinician here, they are coordinated rather than stacked blindly.

Do I need a prescription for peptides?

Yes. Therapeutic peptides are prescription medications, not supplements. They must be prescribed and supervised by a licensed clinician and sourced from a regulated compounding pharmacy. Over-the-counter products marketed as peptides are not the same compounds used in clinical peptide therapy and carry unknown safety risks.

Does peptide therapy work for weight loss?

Some compounds in this category do, and are FDA-approved for it. Others do not, despite marketing suggesting otherwise. If weight is your primary goal, the honest starting point is a metabolic and hormone workup to establish what is actually driving it, rather than assuming a peptide is the answer.

If This Resonates

If your labs keep coming back normal while your recovery, energy and body composition tell a different story, that gap is worth investigating properly rather than being told it is normal aging.

Your first visit is $35, applied toward your treatment plan. Call or text (734) 436-3357. Arbour Longevity is at 2217 Packard St #15, Ann Arbor, MI 48104, open Thursday to Monday 10:00-19:00 and closed Tuesday and Wednesday, serving Ypsilanti, Saline, Dexter, Chelsea, Plymouth, Canton and the wider Washtenaw County area, with telehealth follow-up available for established patients across Michigan.

Book your $35 consultation

References

• Van Cauter E, et al. (2004). Reciprocal interactions between the GH axis and sleep. Growth Hormone & IGF Research, 14 Suppl A, S10-17. PMID 15135771. doi:10.1016/j.ghir.2004.03.006
• Moreno-Reyes R, et al. (1998). Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. American Journal of Physiology, 274(5), E779-84. PMID 9612233. doi:10.1152/ajpendo.1998.274.5.E779
• Teichman SL, et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. PMID 16352683. doi:10.1210/jc.2005-1536
• Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PMID 9849822. doi:10.1530/eje.0.1390552
• Falutz J, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor analog, in patients with excess abdominal fat: pooled analysis of two phase 3 trials. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291-4304. PMID 20554713. doi:10.1210/jc.2010-0490
• Jastreboff AM, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. PMID 35658024. doi:10.1056/NEJMoa2206038
• Kingsberg SA, et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology, 134(5), 899-908. PMID 31599840. doi:10.1097/AOG.0000000000003500
• Seiwerth S, et al. (2018). BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design, 24(18), 1972-1989. PMID 29998800. doi:10.2174/1381612824666180712110447

Citations verified via PubMed. This article is educational and does not replace individualized medical advice. Peptides are prescription medications prescribed and supervised by a clinician. Availability and regulatory status are subject to change, and individual results vary. Arbour Longevity, 2217 Packard St #15, Ann Arbor MI 48104, (734) 436-3357.